2Caro JJ,Salas M, Ward A, et al. Anemia as an independent prog- nostic factor for survival in patients with cancer:a systemic, quali- tative review [ J]. Cancer,2001,91 (12) :2214 - 2221.
3Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembo- lism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-assoclated a- nemia [ J ]. JAMA,2008,299 ( 8 ) : 914 - 924.
4Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis [ J]. CMAJ,2009,180 ( 11 ) : E62 - 71.
5Sinclair AM, Roqers N, Busse L, et al. Erythropoietin receptor tran- scription is neither elevated nor predictive of surface expression in human tumour ceils [ J ]. Br J Cancer,2008,98 ( 6 ) : 1059 - 1067.
6Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double- blind,placebo-controlled trial of recombinant human erythropoie- tin,epoetin Beta, in hematologic malignancies [ J ]. J Clin Oncol, 2002,20 ( 10 ) :2486 - 2494.
7Leyland-Jones B, BEST Investigators and Study Group. Breast canc- er trial with erythropoietin terminated unexpcetedly[ J ]. Lancet On- col,2003,4 ( 8 ) :459.
8Henke M, Laszig R, Rilbe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy:ran- domized, double-blind, placebo-controlled trial [ J ]. Lancet, 2003, 362 (9392) : 1255 - 1260.
9Leyland-Jones B. Evidence for erythropoietin as a molecular targe- ting agent [ J]emin Oncol, 2002,29 ( 3 Suppl. 11 ) : 145 - 154.
10Yasuda Y,Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproduet- ive organs [ J ]. Carcinogenesis,2002,23 ( 11 ) : 1797 - 1805.
